{
    "nctId": "NCT00680758",
    "briefTitle": "Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer",
    "officialTitle": "A Phase I Study of Cisplatin, Paclitaxel, and RAD001 Patients With Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 18,
    "primaryOutcomeMeasure": "Safety profile and maximum tolerated dose",
    "eligibilityCriteria": "Inclusion Criteria:\n\nDISEASE CHARACTERISTICS:\n\n* Histologically confirmed invasive mammary carcinoma\n\n  * Stage IV disease\n* No locally recurrent breast cancer\n* Patients with HER2/neu overexpressing tumors must have received prior trastuzumab (Herceptin\u00ae) in first-line treatment of metastatic breast cancer\n* Patients with estrogen receptor- or progesterone receptor-expressing tumors must have received prior endocrine therapy (i.e., aromatase inhibitors, fulvestrant, tamoxifen, or ovarian ablation) in first-line treatment of metastatic breast cancer\n* No symptomatic brain metastases\n\n  * Patients with a history of brain metastases must be clinically stable and not taking steroids or therapeutic anticonvulsants that are CYP3A4 modifiers\n  * Patients with asymptomatic brain metastases on prophylactic convulsants that are CYP3A4 modifiers are not eligible\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* ECOG performance status 0-1\n* Life expectancy \u2265 6 months\n* ANC \u2265 1000/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n* Creatinine \u2264 1.5 times upper limit of normal (ULN)\n* Bilirubin \u2264 1.5 times ULN (3 times ULN if liver metastasis present)\n* SGOT and SGPT \u2264 1.5 times ULN (3 times ULN if liver metastasis present)\n* Alkaline phosphatase \u2264 3 times ULN if liver metastasis present\n* Able to swallow and retain oral medication\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for 3 months after completion of study treatment\n* Must be disease-free from prior invasive cancers for \\> 5 years with the exception of completely resected basal cell or squamous cell carcinoma of the skin or successfully treated cervical carcinoma in situ\n* No malabsorption syndrome, disease significantly affecting gastrointestinal function, or ulcerative colitis\n* No uncontrolled intercurrent illness including, but not limited to:\n\n  * Ongoing or active infection requiring parenteral antibiotics\n  * Impairment of lung function (i.e., chronic obstructive pulmonary disease or lung conditions requiring oxygen therapy)\n  * Symptomatic New York Heart Association class III-IV congestive heart failure\n  * Unstable angina pectoris, angioplasty, stenting, or myocardial infarction within the past 6 months\n  * Uncontrolled hypertension (systolic blood pressure \\[BP\\] \\> 180 mm Hg or diastolic BP \\> 100 mm Hg)\n  * Clinically significant cardiac arrhythmia (i.e., multifocal premature ventricular contractions, bigeminy, trigeminy, or ventricular tachycardia that is symptomatic or requires treatment)\n  * Uncontrolled diabetes\n  * Psychiatric illness/social situations that would preclude compliance with study requirements\n* No known history of uncontrolled or symptomatic neuropathy \u2265 grade 2\n* No hypersensitivity to paclitaxel, or drugs using the vehicle Cremophor, Chinese hamster ovary cell products, or other recombinant human antibodies\n\nExclusion Criteria:\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* Recovered from all prior treatment\n* Must not have exceeded a total cumulative dose of life-time exposure of doxorubicin hydrochloride \u2264 360 mg/m\u00b2 or epirubicin hydrochloride \u2264 640 mg/m\u00b2\n* At least 2 weeks since other prior investigational drugs\n* No prior resection of the stomach or small bowel\n* No more than 4 prior chemotherapy regimens in the metastatic setting\n\n  * This restriction does not include endocrine therapies or single agent biologic therapies (i.e., trastuzumab)\n* Concurrent radiotherapy to painful bone metastases or areas of impending bone fracture allowed as long as radiotherapy is initiated prior to study entry\n* No concurrent trastuzumab\n* No concurrent endocrine therapy\n* No concurrent CYP3A4 modifiers\n* No concurrent herbal supplement\n* No other concurrent anticancer therapy (chemotherapy, radiotherapy, surgery, immunotherapy, hormonal therapy, or biological therapy)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}